Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to AATD, KAMRAB/KEDRAB a plasma-derived hyper- immunoglobulin for prophylactic treatment against rabies infection. It also provides KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns KamRho (D) IV for immune thermobocytopunic purpura and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes Bramitob to manage chronic pulmonary infection FOSTER to treat asthma PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity IVIG 5% for the treatment of various immunodeficiency-related conditions AeroBika, an OPEP device Varitect, a varicella zoster immunoglobulin Zutectra and Hepatect CP for the prevention of hepatitis B virus Megalotect, a CMV immunoglobulin and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders Albumin and Albumin for maintenance of blood plasma and coagulation factors comprising Factor VIII and Factor IX, IXIARO vaccine, VIVOTIF for immunization against disease caused by salmonella typhi as well as PROCYSBI, LAMZEDE for metabolic disease, and ELIGARD to treat prostate cancer. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited PARI GmbH and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.